All In Biotech

Drug Trial Radar · NCT00094367

A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study)

See Detailed Description

Last checked: Nov 19, 2026Latest source record: Sep 30, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

900

Actual

Start

Jul 2004

Primary completion

Oct 2005

Study completion Oct 2005

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 18, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was designed to evaluate if subjects who took 600 mg of abacavir and 300 mg of lamivudine once-daily as a single tablet were just as likely to have adverse events compared to subjects who took 300 mg of abacavir and 150 mg of lamivudine administered as separate tablets twice-daily.

Conditions

  • HIV Infection

Interventions

  • Abacavir/LamivudineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The occurrence of treatment-limiting adverse events after starting study drugs.

Locations

178 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Montgomery, Alabama

  • GSK Investigational Site

    Glendale, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Tucson, Arizona

  • GSK Investigational Site

    Arleta, California

  • GSK Investigational Site

    Beverly Hills, California

  • GSK Investigational Site

    Beverly Hills, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Long Beach, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Newport Beach, California

  • GSK Investigational Site

    Oakland, California

  • GSK Investigational Site

    Oakland, California

  • GSK Investigational Site

    Palm Springs, California

  • GSK Investigational Site

    Panorama City, California

  • GSK Investigational Site

    Paramount, California

  • GSK Investigational Site

    Riverside, California

  • GSK Investigational Site

    Salinas, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    San Francisco, California

  • GSK Investigational Site

    Santa Rosa, California

  • GSK Investigational Site

    Tarzana, California

  • GSK Investigational Site

    Tarzana, California

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Glastonbury, Connecticut

  • GSK Investigational Site

    New Haven, Connecticut

  • GSK Investigational Site

    Norwalk, Connecticut

  • GSK Investigational Site

    Stamford, Connecticut

  • GSK Investigational Site

    Stratford, Connecticut

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Coral Gables, Florida

Showing 40 of 178 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.